Cardiometabolic disease is the leading global public health challenge. Yet most people living with it do not receive evidence-based care. We exist to close that gap.
Registered charity no. 1216451Charitable Incorporated Organisation · England & WalesFounded 2026No cookies · No tracking
#1Cause of global mortality & morbidity
>75%Of patients unnecessarily remain at higher risk
4Getting to goal on 4 metrics — Adiposity, Blood Pressure, Cholesterol and Diabetes — can substantially reduce risk
The Problem
The Evidence Exists. The Care Doesn't.
Cardiometabolic disease spans cardiovascular disease, diabetes, obesity, hypertension, dyslipidaemia and metabolic renal and hepatic damage.
Effective therapies now exist — yet an implementation gap leaves most patients without guideline-level care. Closing it would benefit millions of people and save billions in healthcare costs.
Conditions
Cardiometabolic
Cardiovascular disease
Diabetes
Obesity
Hypertension
Dyslipidaemia
Renal & hepatic damage
Proven therapies
GLP-1 receptor agonists
SGLT2 inhibitors
PCSK9 inhibitors
Patients unnecessarily at higher risk>75%
Our Mission
To organise the cardiometabolic evidence base and make it universally accessible and actionable — improving the quality and length of life for people at risk.
Our Framework · ABCD & Me
A Comprehensive Framework for Cardio-Kidney-Liver Protection
Cardio-kidney-liver protection requires holistic, interconnected evaluation rather than treating isolated risk markers.
A new charity, founded in 2026 by Dr. Jyothis George and governed by a board of trustees with academic, hospital cardiology and primary care experience.
A global scientific advisory board — including people living with cardiometabolic disease — is being assembled.
We welcome clinicians, researchers, health systems, industry and people with lived experience who share our goal of closing the cardiometabolic care gap.